Research programme: oncolytic virus therapies - Cell Genesys/Genetic Therapy
Alternative Names: CG4030; CG5757Latest Information Update: 01 Jul 2009
At a glance
- Originator Cell Genesys; Genetic Therapy
- Developer Cell Genesys
- Class Oncolytic viruses
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Jun 2009 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 07 Mar 2007 Preclinical development of GC 5757 is ongoing for cancer
- 22 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Cancer pharmacodynamics section